Skip to main content
Log in

Allopurinol use in a New Zealand population: prevalence and adherence

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Allopurinol is effective for the control of gout and its long-term complications when taken consistently. There is evidence that adherence to allopurinol therapy varies across population groups. This may exacerbate differences in the burden of gout on population groups and needs to be accurately assessed. The aim of this study was to describe the prevalence of allopurinol use in a region of New Zealand using community pharmacy dispensing data and to examine the levels of suboptimal adherence in various population groups. Data from all community pharmacy dispensing databases in a New Zealand region were collected for a year covering 2005/2006 giving a near complete picture of dispensings to area residents. Prevalence of allopurinol use in the region by age, sex, ethnicity and socioeconomic position was calculated. Adherence was assessed using the medication possession ratio (MPR), with a MPR of 0.80 indicative of suboptimal adherence. Multiple logistic regression was used to explore variations in suboptimal adherence across population groups. A total of 953 people received allopurinol in the study year (prevalence 3 %). Prevalence was higher in males (6 %) than in females (1 %) and Māori (5 %) than non-Māori (3 %). The overall MPR during the study was 0.88, with 161 (22 %) of patients using allopurinol having suboptimal adherence. Non-Māori were 54 % less likely to have suboptimal allopurinol adherence compared to Māori (95 % CI 0.30–0.72, p = 0.001). These findings are consistent with those from other studies nationally and internationally and point to the important role for health professionals in improving patient adherence to an effective gout treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Notes

  1. There were no medicines in ATC category M04AA51 (allopurinol, combinations) dispensed. No other urate-lowering medicine was available in New Zealand during the study period.

References

  1. Brook RA, Forsythe A, Smeeding JE, Lawrence Edwards N (2010) Chronic gout: epidemiology, disease progression, treatment and disease burden. Curr Med Res Opin 26:2813–2821. doi:10.1185/03007995.2010.533647

    Article  PubMed  Google Scholar 

  2. Smith EUR, Díaz-Torné C, Perez-Ruiz F, March LM (2010) Epidemiology of gout: an update. Best Pract Res Clin Rheumatol 24:811–827. doi:10.1016/j.berh.2010.10.004

    Article  CAS  PubMed  Google Scholar 

  3. Lindsay K, Gow P, Vanderpyl J et al (2011) The experience and impact of living with gout: a study of men with chronic gout using a qualitative grounded theory approach. J Clin Rheumatol 17:1–6. doi:10.1097/RHU.0b013e318204a8f9

    Article  PubMed  Google Scholar 

  4. Winnard D, Kake T, Gow P et al (2008) Debunking the myths to provide 21st Century management of gout. N Z Med J 121:79–85

    PubMed  Google Scholar 

  5. Martini N, Bryant L, Te Karu L et al (2012) Living with gout in New Zealand: an exploratory study into people’s knowledge about the disease and its treatment. J Clin Rheumatol 18:125–129. doi:10.1097/RHU.0b013e31824e1f6f

    Article  PubMed  Google Scholar 

  6. Kleinman NL, Brook RA, Patel PA et al (2007) The impact of gout on work absence and productivity. Value Heal 10:231–237. doi:10.1111/j.1524-4733.2007.00173.x

    Article  Google Scholar 

  7. Winnard D, Wright C, Taylor WJ et al (2012) National prevalence of gout derived from administrative health data in Aotearoa New Zealand. Rheumatology 51:901–909. doi:10.1093/rheumatology/ker361

    Article  PubMed  Google Scholar 

  8. Jackson G, Wright C, Thornley S et al (2012) Potential unmet need for gout diagnosis and treatment: capture-recapture analysis of a national administrative dataset. Rheumatology 51:1820–1824. doi:10.1093/rheumatology/kes147

    Article  PubMed  Google Scholar 

  9. Trifirò G, Morabito P, Cavagna L et al (2012) Epidemiology of gout and hyperuricaemia in Italy during the years 2005–2009: a nationwide population-based study. Ann Rheum Dis. doi:10.1136/annrheumdis-2011-201254

    PubMed  Google Scholar 

  10. Mikuls TR, Saag KG (2006) New insights into gout epidemiology. Curr Opin Rheumatol 18:199–203. doi:10.1097/01.bor.0000209435.89720.7c

    Article  PubMed  Google Scholar 

  11. Robinson PC, Taylor WJ, Merriman TR (2012) A systematic review of the prevalence of gout and hyperuricemia in Australia. Intern Med J 42:997–1007. doi:10.1111/j.1445-5994.2012.02794.x

    CAS  PubMed  Google Scholar 

  12. Rothenbacher D, Primatesta P, Ferreira A et al (2011) Frequency and risk factors of gout flares in a large population-based cohort of incident gout. Rheumatology 50:973–981. doi:10.1093/rheumatology/keq363

    Article  PubMed  Google Scholar 

  13. Dalbeth N, So A (2010) Hyperuricaemia and gout: state of the art and future perspectives. Ann Rheum Dis 69:1738–1743. doi:10.1136/ard.2010.136218

    Article  PubMed  Google Scholar 

  14. Schlesinger N, Dalbeth N, Perez-Ruiz F (2009) Gout–what are the treatment options? Expert Opin Pharmacother 10:1319–1328. doi:10.1517/14656560902950742

    Article  CAS  PubMed  Google Scholar 

  15. Reach G (2011) Treatment adherence in patients with gout. Joint, Bone, Spine 78:456–459. doi:10.1016/j.jbspin.2011.05.010

    Article  PubMed  Google Scholar 

  16. Briesacher BA, Andrade SE, Fouayzi H, Chan KA (2008) Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 28:437–443. doi:10.1592/phco.28.4.437

    Article  PubMed Central  PubMed  Google Scholar 

  17. Solomon DH, Avorn J, Levin R, Brookhart MA (2008) Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis 67:609–613. doi:10.1136/ard.2007.076182

    Article  CAS  PubMed  Google Scholar 

  18. Harrold LR, Andrade SE, Briesacher BA et al (2009) Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther 11:R46. doi:10.1186/ar2659

    Article  PubMed Central  PubMed  Google Scholar 

  19. Dunbar J, Dunning EJ, Dwyer K (1989) Compliance measurement with arthritis regimen. Arthritis Care Res (Hoboken) 2:A8–A16. doi:10.1002/anr.1790020309

    Article  Google Scholar 

  20. Horsburgh S, Malik M, Norris P et al (2009) Prescribing and dispensing data sources in New Zealand: their usage and future directions. School of Pharmacy, Dunedin

    Google Scholar 

  21. Horsburgh S, Norris P, Becket G et al (2010) The equity in prescription medicines use study: using community pharmacy databases to study medicines utilisation. J Biomed Inform 43:982–987. doi:10.1016/j.jbi.2010.08.004

    Article  PubMed  Google Scholar 

  22. Statistics New Zealand (2009) QuickStats about Gisborne District. Statistics New Zealand, Wellington

    Google Scholar 

  23. Salmond C, Crampton P, Atkinson J (2007) NZDep2006 index of deprivation. Department of Public Health, University of Otago, Wellington

  24. Statistics New Zealand (2013) Urban/rural profile (experimental) classification categories. http://www.stats.govt.nz/methods/classifications-and-standards/urban-rural-profile-experimental-class-categories.aspx. Accessed 13 Feb 2013

  25. WHO Collaborating Centre for Drug Statistics Methodology (2007) Guidelines for ATC classification and DDD assignment. WHO Collaborating Centre for Drug Statistics Methodology, Oslo

    Google Scholar 

  26. Apotex NZ Ltd (2011) New Zealand data sheet: Apo-Allopurinol. Apotex NZ Ltd, Auckland

  27. Andrade SE, Kahler KH, Frech F, Chan KA (2006) Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 15:565–574; discussion 575–577. doi: 10.1002/pds.1230

    Google Scholar 

  28. Rothman KJ, Greenland S, Lash TL (2008) Modern epidemiology, 3rd edn. Lippincott Williams & Wilkins, Philadelphia

    Google Scholar 

  29. R Core Team (2012) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna

  30. Dalbeth N, House ME, Horne A et al (2012) The experience and impact of gout in Māori and Pacific people: a prospective observational study. Clin Rheumatol. doi:10.1007/s10067-012-2110-5

    PubMed  Google Scholar 

  31. Harrold LR, Mazor KM, Velten S et al (2010) Patients and providers view gout differently: a qualitative study. Chronic Illn 6:263–271. doi:10.1177/1742395310378761

    Article  PubMed Central  PubMed  Google Scholar 

  32. Spencer K, Carr A, Doherty M (2012) Patient and provider barriers to effective management of gout in general practice: a qualitative study. Ann Rheum Dis 71:1490–1495. doi:10.1136/annrheumdis-2011-200801

    Article  PubMed  Google Scholar 

  33. Ministry of Social Development (2010) The social report. Ministry of Social Development, Wellington

    Google Scholar 

  34. Jatrana S, Crampton P, Norris P (2011) Ethnic differences in access to prescription medication because of cost in New Zealand. J Epidemiol Community Health 65:454–460. doi:10.1136/jech.2009.099101

    Article  PubMed  Google Scholar 

  35. Jatrana S, Crampton P (2009) Primary health care in New Zealand: who has access? Health Policy (New York) 93:1–10. doi:10.1016/j.healthpol.2009.05.006

    Article  Google Scholar 

  36. Dalbeth N, Petrie KJ, House M et al (2011) Illness perceptions in patients with gout and the relationship with progression of musculoskeletal disability. Arthritis Care Res (Hoboken) 63:1605–1612. doi:10.1002/acr.20570

    Article  Google Scholar 

  37. Davis A (2012) Geographical access to medicines in Te Tairawhiti. University of Otago

Download references

Acknowledgments

This work is based on a study funded by the Health Research Council of New Zealand (Grant Number 07/139). The authors would like to thank the pharmacists and people of Gisborne for their advice and the use of their data, as well as the support of Ngati Porou Hauora and Turanga Health. The authors would also like to acknowledge the Local Advisory Committee to the project for their extremely useful insights and comments.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Simon Horsburgh.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 29 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Horsburgh, S., Norris, P., Becket, G. et al. Allopurinol use in a New Zealand population: prevalence and adherence. Rheumatol Int 34, 963–970 (2014). https://doi.org/10.1007/s00296-013-2935-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-013-2935-5

Keywords

Navigation